

Ugo Moretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/52035/publications.pdf>

Version: 2024-02-01

35
papers

991
citations

471061

17
h-index

454577

30
g-index

40
all docs

40
docs citations

40
times ranked

1250
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 51.	1.0	8
2	Assessment of adverse reactions to α -lipoic acid containing dietary supplements through spontaneous reporting systems. <i>Clinical Nutrition</i> , 2021, 40, 1176-1185.	2.3	18
3	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and Vigibase. <i>Vaccines</i> , 2021, 9, 19.	2.1	11
4	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1421-1431.	1.0	9
5	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. <i>BioDrugs</i> , 2021, 35, 749-764.	2.2	16
6	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. <i>Drug Safety</i> , 2021, 44, 1247-1269.	1.4	85
7	Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017. <i>Scientific Reports</i> , 2020, 10, 14122.	1.6	2
8	Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database. <i>Frontiers in Pharmacology</i> , 2020, 11, 622862.	1.6	16
9	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. <i>Clinical Nutrition</i> , 2020, 39, 3854-3855.	2.3	1
10	Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase [®] . <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1099-1108.	1.0	28
11	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
12	Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database. <i>European Journal of Pediatrics</i> , 2019, 178, 161-172.	1.3	1
13	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. <i>Drug Safety</i> , 2019, 42, 347-363.	1.4	65
14	No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. <i>Expert Review of Vaccines</i> , 2018, 17, 363-381.	2.0	7
15	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 533-542.	1.1	83
16	From narrative descriptions to MedDRA: automatically encoding adverse drug reactions. <i>Journal of Biomedical Informatics</i> , 2018, 84, 184-199.	2.5	21
17	Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?. <i>Drug Safety</i> , 2016, 39, 883-890.	1.4	43
18	Italian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 69-75.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 238-248.	1.1	59
20	Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 61-67.	1.0	11
21	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. <i>Drug Safety</i> , 2016, 39, 59-68.	1.4	25
22	Authors' Reply to Alain Brailon's Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project". <i>Drug Safety</i> , 2016, 39, 367-368.	1.4	0
23	Automagically Encoding Adverse Drug Reactions in MedDRA. , 2015, , .		10
24	Mining approximate temporal functional dependencies with pure temporal grouping in clinical databases. <i>Computers in Biology and Medicine</i> , 2015, 62, 306-324.	3.9	21
25	Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 285-293.	1.1	66
26	Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from Vigibase®. <i>Drug Safety</i> , 2015, 38, 889-894.	1.4	20
27	Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe. <i>PLoS ONE</i> , 2015, 10, e0119551.	1.1	49
28	Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001 - 2012. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 9-20.	1.0	36
29	Consultancy and surveillance of post-immunisation adverse events in the Veneto region of Italy for 1992-2008. <i>Hum Vaccin</i> , 2011, 7, 234-239.	2.4	13
30	Cosmetovigilance. <i>Drug Safety</i> , 2008, 31, 437-439.	1.4	5
31	Assessment of the Risk of Fragrance Allergy in the General Population. <i>Drug Safety</i> , 2008, 31, 440-443.	1.4	7
32	Statin-Associated Psychiatric Adverse Events. <i>Drug Safety</i> , 2008, 31, 1115-1123.	1.4	1
33	Adverse Drug Reactions Related to the Use of NSAIDs with a Focus on Nimesulide. <i>Drug Safety</i> , 2001, 24, 1081-1090.	1.4	39
34	Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 839-846.	1.1	140
35	Spontaneous reporting of adverse drug reactions in an Italian region: Six years of analysis and observations. <i>Pharmacoepidemiology and Drug Safety</i> , 1995, 4, 129-135.	0.9	3